cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.30486935.v1
title: Supplementary Material for: Validity and discriminative value of activity questionnaires in youth with Type 1 Diabetes

description: Introduction: Prospective data quantifying physical activity levels in Australian youth with T1D is lacking. Structured questionnaire instruments may provide useful information but have not been evaluated in youth with type 1 diabetes (T1D). The objective of this study was to evaluate the validity of three paediatric physical activity (PA) questionnaires in young people with T1D and their ability to differentiate those not meeting PA guidelines of 60 minutes of moderate-to-vigorous PA (MVPA) per day from those who do.

Methods: Eighty youth with T1D (42 boys, 38 girls; age: 13.1 ± 2.6 years; BMI: 20.2 ± 3.9 kg.m-2; HbA1c: 58.5 ± 10.1 mmol/mol, T1D duration: 5.4 ± 3.1 years) wore an Actigraph GT3x accelerometer for 7 days and on day 8 completed three self-report PA instruments; i) the Physical Activity Questionnaire (PAQ); ii) Previous Day Physical Activity Recall (PDPAR) and; iii) a single item physical activity scale (SIPAS). Validity coefficients for each instrument using accelerometry-derived MVPA minutes were determined using Spearman’s correlation coefficient. Receiver operator characteristic (ROC) curves were generated and optimal cut-points determined.

Results: Mean daily MVPA minutes were 46.6 ± 25.5 minutes; 21/80 participants (26%) achieved an average of ≥ 60 MVPA minutes per day. The PAQ had the highest validity coefficient (r = 0.53; p &lt; 0.001), followed by the single item tool (r = 0.39; p &lt; 0.001) and PDPAR (r = 0.09; p = 0.4). Area under the ROC curve was 0.7, 0.5, and 0.7 for the PAQ, PDPAR, and single-item tools, respectively. Optimal cut points for sensitivity and specificity were i) a PAQ composite score of 2.8 (66.1% and 66.7%), ii) 75 MVPA minutes on the PDPAR (59.3% and 47.6%), and iii) 4.5 days on the SIPAS (71.2% and 38.1%).

Conclusion: The PAQ has moderate to high criterion validity and showed moderate ability to discriminate between T1D youth meeting PA guidelines from those who do not. The single-item question had low to moderate construct validity, while the PDPAR did not correlate with objectively measured PA levels. The feasibility of incorporating the PAQ into clinical care for youth with T1D warrants further evaluation.
DOI: 10.6084/m9.figshare.30486938
title: Supplementary Material for: Visceral Adiposity and Risk of Depression Independent of General and Central Adiposity: A Prospective Cohort Study

description: Objective: Visceral adipose tissue (VAT) is a metabolically active fat depot linked to cardiometabolic disease, but its relationship with depression independent of general and central adiposity remains unclear. We investigated the association of MRI-quantified VAT with incidence of depression and evaluated whether it predicts depression risk beyond body mass index (BMI) and waist-to-height ratio (WHtR).
Methods: We analyzed 50,729 UK Biobank participants who underwent abdominal MRI between 2014 and 2020. Baseline VAT volume, BMI, and WHtR were measured, and incidence of depression was ascertained. Cox proportional hazards models estimated hazard ratios (HRs) for depression, and restricted cubic splines assessed potential non-linear associations. Mediation analyses quantified the extent to which VAT accounted for associations of BMI and WHtR with depression.
Results: Over a median follow-up of 15.4 years, each 1-SD higher VAT was associated with a 29% increased risk of depression (HR, 1.29; 95% CI, 1.19–1.39), independent of sociodemographic, behavioral, and clinical factors. Participants in the highest VAT quartile had nearly double the risk compared with the lowest quartile. BMI and WHtR showed non-linear associations but were not independently associated with depression after adjusting for VAT. VAT provided superior predictive value compared with BMI and WHtR, and mediation analyses indicated that it accounted for most of their observed associations.
Conclusions: Visceral adiposity, rather than general (BMI-defined) or central (WHtR-defined) adiposity, is the principal adipose-related predictor of depression risk. These findings highlight VAT as the principal adiposity measure for risk assessment and a potential target for prevention.
DOI: 10.6084/m9.figshare.30486938.v1
title: Supplementary Material for: Visceral Adiposity and Risk of Depression Independent of General and Central Adiposity: A Prospective Cohort Study

description: Objective: Visceral adipose tissue (VAT) is a metabolically active fat depot linked to cardiometabolic disease, but its relationship with depression independent of general and central adiposity remains unclear. We investigated the association of MRI-quantified VAT with incidence of depression and evaluated whether it predicts depression risk beyond body mass index (BMI) and waist-to-height ratio (WHtR).
Methods: We analyzed 50,729 UK Biobank participants who underwent abdominal MRI between 2014 and 2020. Baseline VAT volume, BMI, and WHtR were measured, and incidence of depression was ascertained. Cox proportional hazards models estimated hazard ratios (HRs) for depression, and restricted cubic splines assessed potential non-linear associations. Mediation analyses quantified the extent to which VAT accounted for associations of BMI and WHtR with depression.
Results: Over a median follow-up of 15.4 years, each 1-SD higher VAT was associated with a 29% increased risk of depression (HR, 1.29; 95% CI, 1.19–1.39), independent of sociodemographic, behavioral, and clinical factors. Participants in the highest VAT quartile had nearly double the risk compared with the lowest quartile. BMI and WHtR showed non-linear associations but were not independently associated with depression after adjusting for VAT. VAT provided superior predictive value compared with BMI and WHtR, and mediation analyses indicated that it accounted for most of their observed associations.
Conclusions: Visceral adiposity, rather than general (BMI-defined) or central (WHtR-defined) adiposity, is the principal adipose-related predictor of depression risk. These findings highlight VAT as the principal adiposity measure for risk assessment and a potential target for prevention.
DOI: 10.6084/m9.figshare.30486941
title: Supplementary Material for: Efficacy of Electroacupuncture Combined with Pregabalin in the Treatment of Trigeminal Herpetic Neuralgia: a Multicenter Randomized Controlled Trial Study Protocol

description: Abstract
Background: Trigeminal herpetic neuralgia, a common type of Zoster-associated Pain (ZAP), affects individuals across all ages groups and poses a significant societal burden all over the world. Electroacupuncture (EA) is increasingly used in the treatment of ZAP due to its affordability, high safety profile, absence of adverse reactions, and high patient acceptance. Consequently, it is essential to conduct randomized controlled trials to evaluate the efficacy and safety of EA in treating ZAP and to determine if EA can be used as an alternative to pregabalin.
Patients and Methods: A total of 102 patients with trigeminal herpetic neuralgia will be enrolled from 2 hospitals and randomly assigned to the EA group, pregabalin group, or EA + pregabalin group in a 1:1:1 ratio using a simple random number table. The study will consist of a 4-week treatment period followed by a 4-week follow-up period. The primary outcome measure will be pain intensity, while secondary outcomes will include mood state, sleep quality, and quality of life. Adverse reactions will be thoroughly evaluated.
Conclusion: This study aims to elucidate the clinical efficacy of EA combined with pregabalin for trigeminal herpetic neuralgia and to objectively compare the efficacy and safety of EA versus oral pregabalin in the treatment of trigeminal herpetic neuralgia.
Ethics and Dissemination: Ethical approval has been obtained from the Ethics Committee of Hangzhou Third People's Hospital (No.2023KA010). Informed consent will be obtained from all participants prior to enrollment. The trial results will be published in international journals and presented at relevant international conferences.
Trial Registration Number: This protocol has been registered in the China Clinical Trial Registration Center with the identification code NCT06261801.
DOI: 10.6084/m9.figshare.30486941.v1
title: Supplementary Material for: Efficacy of Electroacupuncture Combined with Pregabalin in the Treatment of Trigeminal Herpetic Neuralgia: a Multicenter Randomized Controlled Trial Study Protocol

description: Abstract
Background: Trigeminal herpetic neuralgia, a common type of Zoster-associated Pain (ZAP), affects individuals across all ages groups and poses a significant societal burden all over the world. Electroacupuncture (EA) is increasingly used in the treatment of ZAP due to its affordability, high safety profile, absence of adverse reactions, and high patient acceptance. Consequently, it is essential to conduct randomized controlled trials to evaluate the efficacy and safety of EA in treating ZAP and to determine if EA can be used as an alternative to pregabalin.
Patients and Methods: A total of 102 patients with trigeminal herpetic neuralgia will be enrolled from 2 hospitals and randomly assigned to the EA group, pregabalin group, or EA + pregabalin group in a 1:1:1 ratio using a simple random number table. The study will consist of a 4-week treatment period followed by a 4-week follow-up period. The primary outcome measure will be pain intensity, while secondary outcomes will include mood state, sleep quality, and quality of life. Adverse reactions will be thoroughly evaluated.
Conclusion: This study aims to elucidate the clinical efficacy of EA combined with pregabalin for trigeminal herpetic neuralgia and to objectively compare the efficacy and safety of EA versus oral pregabalin in the treatment of trigeminal herpetic neuralgia.
Ethics and Dissemination: Ethical approval has been obtained from the Ethics Committee of Hangzhou Third People's Hospital (No.2023KA010). Informed consent will be obtained from all participants prior to enrollment. The trial results will be published in international journals and presented at relevant international conferences.
Trial Registration Number: This protocol has been registered in the China Clinical Trial Registration Center with the identification code NCT06261801.
DOI: 10.6084/m9.figshare.30486944
title: Supplementary Material for: Efficacy of biomedical materials for the prevention of lymphocele after lymph node dissection for gynecological malignancies: A systematic review and meta-analysis of randomized controlled trials

description: Introduction:
Lymphocele is one of the complications after lymphadenectomy for female pelvic malignancies. In recent years, some studies indicated that the use of biomedical materials during surgery for gynecological malignancies may help to reduce the occurrence of lymphatic cysts, but results were inconsistent. The aim of the present study was to evaluate the correlation between the use of biomedical materials intraoperatively and formation of lymphocele after lymph node dissection in patients with gynecological malignancies. 

Methods:
A systematic search of 4 electronic databases for articles published up to April 14, 2025 was performed. All randomized controlled clinical trials (RCTs) which reported lymphocele outcomes after application of biomedical materials for patients who underwent lymphadenectomy for gynecological malignancies, were finally included in the present meta-analysis. Statistical meta-analysis was performed using the RevMan 5.3 software. 

Results:
Ten randomized controlled studies were finally included in the present study. A total of 879 patients (from 10 studies) with gynecological cancer who underwent pelvic lymph node dissection and/or para-aortic lymph node dissection were included in the meta-analysis. Pelvic lymphoceles were diagnosed in 249 patients (28.3%). The symptomatic lymphocele incidence proportion was 6.4% (47/731). The lymphocele incidence of biomedical material group was significant lower compared with control group (432 vs 447 cases, OR 0.68, 95% CI 0.50-0.93, p = 0.02, data derived from 10 studies), while symptomatic lymphocele incidence was not significantly different between the two groups (358 vs 373 cases, OR 0.66, 95% CI 0.39-1.10, p = 0.11, data derived from 9 studies). In the subgroup analysis, the incidence difference of lymphoceles between the biomedical material group and control group showed significant association with extension of nodes dissection (p＝0.02) and diagnosis time after surgery (p＝0.02). 

Conclusions 
The present meta-analysis supports that the use of biomedical materials is effective in reducing the incidence of lymphocele after lymphadenectomy due to gynecologic cancer, and subgroup analysis found the reduction was more significant in the group without para-aortic lymph node dissection, and in the short term after surgery. Further well-designed clinical studies are required to confirm our conclusions.
DOI: 10.6084/m9.figshare.30486944.v1
title: Supplementary Material for: Efficacy of biomedical materials for the prevention of lymphocele after lymph node dissection for gynecological malignancies: A systematic review and meta-analysis of randomized controlled trials

description: Introduction:
Lymphocele is one of the complications after lymphadenectomy for female pelvic malignancies. In recent years, some studies indicated that the use of biomedical materials during surgery for gynecological malignancies may help to reduce the occurrence of lymphatic cysts, but results were inconsistent. The aim of the present study was to evaluate the correlation between the use of biomedical materials intraoperatively and formation of lymphocele after lymph node dissection in patients with gynecological malignancies. 

Methods:
A systematic search of 4 electronic databases for articles published up to April 14, 2025 was performed. All randomized controlled clinical trials (RCTs) which reported lymphocele outcomes after application of biomedical materials for patients who underwent lymphadenectomy for gynecological malignancies, were finally included in the present meta-analysis. Statistical meta-analysis was performed using the RevMan 5.3 software. 

Results:
Ten randomized controlled studies were finally included in the present study. A total of 879 patients (from 10 studies) with gynecological cancer who underwent pelvic lymph node dissection and/or para-aortic lymph node dissection were included in the meta-analysis. Pelvic lymphoceles were diagnosed in 249 patients (28.3%). The symptomatic lymphocele incidence proportion was 6.4% (47/731). The lymphocele incidence of biomedical material group was significant lower compared with control group (432 vs 447 cases, OR 0.68, 95% CI 0.50-0.93, p = 0.02, data derived from 10 studies), while symptomatic lymphocele incidence was not significantly different between the two groups (358 vs 373 cases, OR 0.66, 95% CI 0.39-1.10, p = 0.11, data derived from 9 studies). In the subgroup analysis, the incidence difference of lymphoceles between the biomedical material group and control group showed significant association with extension of nodes dissection (p＝0.02) and diagnosis time after surgery (p＝0.02). 

Conclusions 
The present meta-analysis supports that the use of biomedical materials is effective in reducing the incidence of lymphocele after lymphadenectomy due to gynecologic cancer, and subgroup analysis found the reduction was more significant in the group without para-aortic lymph node dissection, and in the short term after surgery. Further well-designed clinical studies are required to confirm our conclusions.
DOI: 10.6084/m9.figshare.30486947
title: Supplementary Material for: Clinical Impact of Genetic Alterations in Pediatric Papillary Thyroid Carcinoma: A Next-Generation Sequencing Study from Argentina

description: Background: In children, papillary thyroid cancer (PTC) is generally sporadic and may, less frequently, be part of an undiagnosed hereditary tumor predisposition syndrome. Somatic molecular testing is useful to understand tumor etiology and behavior, predict prognosis, and possibly guide development of novel treatment strategies. The aims of our study were to analyze the findings of a next-generation sequencing (NGS) panel in a cohort of pediatric PTC from Argentina according to age at presentation, recurrence risk, and response to treatment. 
Material and Methods: A retrospective descriptive study was conducted of 63 consecutive pediatric patients with PTC seen at a single center in whom a DNA-based NGS panel was performed. The patients were classified according to the ATA-2015 recurrence risk stratification into a low (n:10), an intermediate (n:13), and a high-risk group (n:40). All patients were treated with total thyroidectomy and radioiodine. At the last follow-up, patients were classified as excellent response (ER) or having persistent disease (PD). 
Results: In 70% (44/63) of the samples, a pathogenic somatic variant was detected, the most frequent alterations were RET fusions (20%). Fusions were more frequent in younger patients (median age 11.45 vs 13.7 years; p:0.048), in diffuse sclerosing subtype histology (p:0.01) and in high-recurrence risk group (p&lt;0.014). The risk of PD was higher in patients in the high-risk group (odds ratio, 9.2). 
When evaluating treatment response based on molecular findings, we found that among the 25 patients who achieved ER, 12 (48%) had fusions and 13 (52%) had point variants, with no statistically significant difference. However, among the 19 patients with PD, 12 (64%) had fusions and 7 (36%) had point variants, a difference that was statistically significant (p &lt; 0.01). 
In 5/63 (8%), pathological germline mutations were observed in genes associated with hereditary tumor predisposition syndromes (HTPS): DICER1 (n:2), PTEN (n:1), and MSH6 (n:2). 
Conclusions: Interestingly, in our PTC cohort the NGS panel was highly specific to detect molecular alterations. Fusions were more frequent at a younger age and in the ATA-2015 high-recurrence-risk group; however, it was not a determining factor to predict PTC outcome. Finally, detection of pathological germline mutations in genes involved in HTPS was useful for genetic counselling.
DOI: 10.6084/m9.figshare.30486947.v1
title: Supplementary Material for: Clinical Impact of Genetic Alterations in Pediatric Papillary Thyroid Carcinoma: A Next-Generation Sequencing Study from Argentina

description: Background: In children, papillary thyroid cancer (PTC) is generally sporadic and may, less frequently, be part of an undiagnosed hereditary tumor predisposition syndrome. Somatic molecular testing is useful to understand tumor etiology and behavior, predict prognosis, and possibly guide development of novel treatment strategies. The aims of our study were to analyze the findings of a next-generation sequencing (NGS) panel in a cohort of pediatric PTC from Argentina according to age at presentation, recurrence risk, and response to treatment. 
Material and Methods: A retrospective descriptive study was conducted of 63 consecutive pediatric patients with PTC seen at a single center in whom a DNA-based NGS panel was performed. The patients were classified according to the ATA-2015 recurrence risk stratification into a low (n:10), an intermediate (n:13), and a high-risk group (n:40). All patients were treated with total thyroidectomy and radioiodine. At the last follow-up, patients were classified as excellent response (ER) or having persistent disease (PD). 
Results: In 70% (44/63) of the samples, a pathogenic somatic variant was detected, the most frequent alterations were RET fusions (20%). Fusions were more frequent in younger patients (median age 11.45 vs 13.7 years; p:0.048), in diffuse sclerosing subtype histology (p:0.01) and in high-recurrence risk group (p&lt;0.014). The risk of PD was higher in patients in the high-risk group (odds ratio, 9.2). 
When evaluating treatment response based on molecular findings, we found that among the 25 patients who achieved ER, 12 (48%) had fusions and 13 (52%) had point variants, with no statistically significant difference. However, among the 19 patients with PD, 12 (64%) had fusions and 7 (36%) had point variants, a difference that was statistically significant (p &lt; 0.01). 
In 5/63 (8%), pathological germline mutations were observed in genes associated with hereditary tumor predisposition syndromes (HTPS): DICER1 (n:2), PTEN (n:1), and MSH6 (n:2). 
Conclusions: Interestingly, in our PTC cohort the NGS panel was highly specific to detect molecular alterations. Fusions were more frequent at a younger age and in the ATA-2015 high-recurrence-risk group; however, it was not a determining factor to predict PTC outcome. Finally, detection of pathological germline mutations in genes involved in HTPS was useful for genetic counselling.
DOI: 10.6084/m9.figshare.30486950
title: Supplementary Material for: Drug-induced interstitial lung disease: a real-world pharmacovigilance study based on an adverse event reporting system

description: Background and Objective Drug-induced interstitial lung disease(DILD) involves different pathogenic mechanisms and it is difficult for clinicians to identify the culprit drug. There is currently no systematic research that allows us to understand the comprehensive situation of potential risk drugs and culprit drugs for DILD.
Methods This study retrospectively analyzed all adverse events related to DILD in FAERS, compiled a list of potential risk drugs leading to DILD and calculated the reporting ratio. In addition, all drugs within the list were detected using disproportionality analysis, a list of culprit drugs was developed based on the signal detection results, and the signal distribution characteristics were summarized. 
Results We obtained 108891 DILD-related reports and identified 1445 potential risk drugs from them. Overall, the drug with the highest number of reports was methotrexate, followed by amiodarone, nivolumab, pembrolizumab, and rituximab. Classifying all potential risk drugs (second level ATC subgroup), the subgroup with the highest number of reports is antineoplastic agents. Finally, we determined the list of culprit drugs, and 171 drugs showed positive signals by signal detection, while the other 1274 drugs were determined to be negative, with amiodarone obtaining the highest number of positive signals. Classify all the culprit drugs and distribute them positively and negatively. The number of drugs with positive signals is less than that with negative signals, and antineoplastic agents (L01) have the highest proportion among all positive drugs. 
Conclusion This study comprehensively displays all drugs related to DILD from a landscape perspective, promoting the rational use of drugs in clinical practice.